Log in to save to my catalogue

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to...

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2703984804

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

About this item

Full title

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

Publisher

Basel, Switzerland: S. Karger AG

Journal title

Liver cancer (Basel ), 2022-07, Vol.11 (4), p.383-396

Language

English

Formats

Publication information

Publisher

Basel, Switzerland: S. Karger AG

More information

Scope and Contents

Contents

Objective: There is limited information regarding the benefits of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for unresectable hepatocellular carcinoma (u-HCC). We compared the efficacy and safety of LEN-TACE sequential therapy to LEN monotherapy and investigated the factors contributing to the LEN-TACE sequent...

Alternative Titles

Full title

Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2703984804

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2703984804

Other Identifiers

ISSN

2235-1795

E-ISSN

1664-5553

DOI

10.1159/000522424

How to access this item